Insurance Plans Favored Higher-Emission Inhalers
Most commercial U.S. insurance plans restrict access to lower-emission asthma inhalers through prior authorization requirements.
Updated on Sept. 28, 2026 in Asthma
Live Poll
Should insurance companies prioritize covering lower-emission inhalers over cheaper, higher-emission alternatives?
A study of 31,219 commercial insurance plans found that most favor metered-dose inhalers over propellant-free alternatives, which have a lower environmental impact. These restrictions limit patient access to environmentally friendly options across the United States.
Why it matters
Insurance coverage structures frequently impose barriers like step therapy on lower-emission inhalers, complicating efforts to manage asthma in an environmentally conscious way. The findings highlight a disparity between clinical preference and the economic realities of drug formularies.
Researchers examined 31,219 U.S. commercial insurance plans to compare coverage for inhaler types. The analysis revealed that propellant-free short-acting beta2-agonist inhalers were significantly less likely to receive tier 1 or 2 coverage compared to traditional metered-dose versions.
The players
Veterans Health Administration
The integrated healthcare system for U.S. military veterans that successfully adjusted its formulary to reduce greenhouse gas emissions.
Rutgers
The university where researchers conducted the insurance plan analysis.
The details
Metered-dose inhalers often rely on chemical propellants that have higher global warming potential than the dry-powder or propellant-free devices. While propellant-free options exist, commercial formularies commonly require prior authorization or step therapy for these products, driving up out-of-pocket costs or administrative hurdles for patients. In contrast, the Veterans Health Administration demonstrated that renegotiating formularies to prioritize specific device types can lead to a 68% reduction in inhaler-related emissions over a 15-year period.
Timeline
2008-2023: The Veterans Health Administration achieved a 68% drop in inhaler-related emissions.
2021: The Veterans Health Administration replaced specific metered-dose inhalers with dry-powder options.
May 2026: Researchers completed the evaluation of 31,219 commercial plan formularies.
Health Landscape
This research highlights a significant gap between the environmental strategies adopted by large public systems and the current standard of commercial insurance coverage. It underscores how administrative hurdles in the private sector continue to favor traditional inhalers despite the success of the Veterans Health Administration formulary emissions reduction program.
If you are interested in using a lower-emission inhaler, check your insurance plan's formulary or contact your provider to see if it requires prior authorization. It is worth discussing your inhaler device options with your doctor to determine if a different, equally effective alternative is available.
The takeaway
Insurance restrictions often favor older, higher-emission inhalers, making it harder for patients to choose environmentally friendly alternatives. When reviewing your asthma treatment plan, ask your physician if your insurance covers propellant-free options and whether they are appropriate for your care.
Further reading
For more information on managing your respiratory care, visit the Asthma section for expert guidance.
Source note: This article includes information reported by MedPage Today.
Live Poll
Should insurance companies prioritize covering lower-emission inhalers over cheaper, higher-emission alternatives?
